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Abstract: Hecogenin is a steroidal sapogenin largely drawn from the plants of the genus 
Agave, commonly known as ‘sisal’, and is one of the important precursors used by the 
pharmaceutical industry for the synthesis of steroid hormones. Hecogenin acetate (HA) is a 
steroidal sapogenin-acetylated that produces antinociceptive activity. Thus, we evaluate the 
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antihyperalgesic profile of HA in mice in inflammatory models, as well as its possible 
involvement with c-fos expression on spinal cord area and cytokines to produces analgesic 
profile. Acute pretreatment with HA (5, 10, or 20 mg/kg; i.p.) inhibited the development of 
mechanical hyperalgesia induced by carrageenan, TNF-α, dopamine and PGE2. Additionally, 
the immunofluorescence data demonstrated that acute pretreatment with HA, at all doses 
tested, significantly inhibited Fos-like expression in the spinal cord dorsal horn normally 
observed after carrageenan-inflammation. Moreover, HA did not affect the motor 
performance of the mice as tested in the Rota rod test. This antinociceptive profile seems to 
be related, at least in part, to a reduction of pro-inflammatory cytokines, as IL-1β. The 
present results suggest that HA attenuates mechanical hyperalgesia by blocking the neural 
transmission of pain at the spinal cord levels and by cytokines-inhibitory mechanisms. 
Keywords: hecogenin acetate; steroidal sapogenin; spinal cord; c-fos; IL-1β; pain 
 
1. Introduction 
Pain management remains one of the greatest challenges of contemporary medicine, nevertheless, 
there are a relatively limited list of treatment options for pain [1]. Although a considerable number of 
analgesic drugs are available for the treatment of painful disorders, the search for development of new 
compounds as therapeutic alternatives continues since the available analgesic drugs exert a wide range 
of side effects [2,3]. In this regard, opioids and nonsteroidal anti-inflammatory drugs (NSAIDs) have 
been the main stay of pain treatment. Presently, there is concern that success in the development of 
new analgesic agents is limited [1].  
Although the expansion of synthetic medicinal chemistry in the last decades caused the proportion 
of new drugs based on natural products to drop to ~50%, 13 natural product–derived drugs were 
approved in the U.S. Food and Drug Administration (FDA) between 2005 and 2007, with five of them 
being the first members of new classes [4]. For the treatment of pain the latest example of the natural 
product approved by FDA is Ziconotide (Prialt®), a peptide toxin obtained from Conus magus (marine 
gastropod mollusk in the family Conidae), and it is the first member in the new drug class of selective 
N-type voltage-sensitive calcium-channel blockers [5]. Currently, because of their relatively low cost 
and easy availability in several countries (mainly developing countries), natural products could be used 
as synthetic models of more selective and powerful drugs [6–8]. 
Hecogenin is a steroidal sapogenin largely drawn from the plants of the genus Agave (commonly 
known as ‘sisal’), and belongs to family Agavaceae, widely distributed in tropical and subtropical 
regions throughout the world [9]. ‘Sisal’ species possess both commercial importance (as source of 
industrial fibers) and medicinal importance and they have been used in Chinese medicine for the 
treatment of scabies and tumors, as well as for painful and inflammatory conditions [10,11]. The 
steroidal sapogenins obtained from ‘sisal’ species (mainly diosgenin and hecogenin) are important 
precursors used by the pharmaceutical industry for the synthesis of steroid hormones, such as adrenal 
cortical hormones (cortisone, cortisol, prednisolone, prednisone, dexamethasone, betamethasone, 
triamcinolone, etc.), sexual hormones (progesterone), and protein anabolic hormones (stanozolol, 
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methandienone) [12–14]. However, there is little scientific information about the biological properties 
of hecogenin in painful and inflammatory conditions. Peana et al. [15] demonstrated hecogenin 
reduced paw edema induced by carrageenin, but also produced gastric mucous lesions in higher doses. 
Cerqueira et al. [16] proposed that the anti-inflammatory property of hecogenin was produced by 
COX-2 inhibition. Conversely, theses authors demonstrated that pretreatment with hecogenin produced 
significant gastroprotective profile mediated by K+ATP channels.  
Recently, our group reported that hecogenin acetate (HA) (Figure 1), a steroidal sapogenin-
acetylated, possesses antinociceptive activity using the tail-flick test and suggested the possible 
involvement of descending pain-inhibitory mechanisms [17]. Now, the antinociceptive effect of HA 
was investigated in inflammatory hyperalgesia models on mice, examining HA-evoked cFos 
immunoreactivity in spinal cords levels and cytokines enhancement by RT-PCR technique. We 
hypothesized that HA may be acting by spinal cord inhibitory mechanisms to produces anti-hyperalgesic 
profile and that the reduction of proinflammatory cytokines may contribute to this analgesic effect. 
Figure 1. Chemical structure of hecogenin acetate. 
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2. Results and Discussion 
The current study shows that systemic administration of hecogenin acetate (HA) could able to 
reduced inflammatory hyperalgesia in a dose-dependent manner and its reduce fos expression in the 
dorsal horn of the spinal cord normally produced by carrageenan suggesting it reduces central excitability.  
As showed in Figure 2, intraplantar injection of carrageenan (300 µg/paw) induced a significant 
increase in the number of responses to 0.6 g force applied to the inflamed hindpaw when compared to 
baseline. The increased number of responses was maintained from 30 to 180 min after the carrageenan 
administration. The systemic administration of HA (5, 10 or 20 mg/kg, i.p.) produced an  
anti-hyeralgesic effect in this model. Specifically mice treated with HA, all doses, 30 min before 
carrageenan administration exhibited a significant reduction in the number of responses to repeated 
application of the 0.6 g mechanical force at all evaluated times, when compared with animals  
vehicle-treated (control group). As expected, the reference drug (indomethacin, 10 mg/kg, i.p.) showed 
reductions in the number of responses to the 0.6 g force (Figure 2A). The group of animals that 
received saline in the sub plantar region, instead of carrageenan, did not present any alteration on the 
threshold of sensitivity towards the mechanical stimuli (data not shown). 
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Figure 2. Effect of the acute administration of vehicle, hecogenin acetate (HA, 5, 10 or  
20 mg/kg; i.p.) or reference drugs (indomethacin—10 mg/kg; i.p. or dipyrone—60 mg/kg, 
i.p.) on mechanical hyperalgesia induced by carrageenan (A), TNF-α (B), dopamine (C) or 
PGE2 (D). Each point represents the mean ± SEM of the paw withdrawal threshold  
(in grams) to tactile stimulation of the ipsilateral hind paw. * p < 0.05, ** p < 0.01 and  
*** p < 0.001 versus control group (ANOVA followed by Tukey test). 
 
 
 
 
The inhibitory effect of HA (5, 10 or 20 mg/kg, i.p.) on the mechanical hyperalgesia induced by 
TNF-α is shown in Figure 2B. Hecogenin acetate (5, 10 or 20 mg/kg) was able to reduce mechanical 
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hyperalgesia induced by TNF-α, when compared with animals of the control group (vehicle-treated), 
similarly to the reference drug (indomethacin, 10 mg/kg, i.p.). Figure 2C shows the inhibitory effect of 
HA on the mechanical hyperalgesia induced by dopamine. HA, in a higher dose, was able to reduce 
mechanical hyperalgesia induced by dopamine, when compared with animals of the vehicle group. 
Intraplantar administration of PGE2 induced a marked mechanical hypersensitivity that was 
significantly reduced by dipyrone (60 mg/kg, i.p.) and by hecogenin acetate at 5–20 mg/kg, as shown 
in Figure 2D. The analgesic potency of hecogenin acetate attributed to its ability to inhibit  
pro-inflammatory cytokines production and seems to be comparable to dipyrone and indomethacin at 
higher doses. However, future studies should further evaluate the potency of hecogenin acetate 
compared to other drugs reference. 
Hyperalgesia induced by i.pl. injection of carrageenan is widely used for evaluating new  
anti-hyperalgesic drugs in rodents [18]. In experiments using mice, injection of carrageenan into the 
plantar surface of animal hind paws produced inflammation and hyperalgesia with similar temporal 
profile [19]. In this model, there is the occurrence of non-immunereaction, involving inflammatory 
mediators, including arachidonic acid products (PGE2), mast cells products (histamine, 5-HT), 
neuropeptides, cytokines (IL-1β and TNFα), NO, nerve growth factor (NGF), leukotrienes B4 (LTB4) 
and transcription factors (NF-κB) [20,21]. According to Cunha et al. [22], this cascade of signalization 
leads to the release of prostanoids and sympathomimetic amines. Therefore, those final inflammatory 
mediators can activate peripheral Aδ and C fiber sensory nerve terminals, thus causing the release of 
substance P and neurokinin A, leading to increases in local blood flow and vascular permeability [23]. 
Cytokines produced after i.pl. injection of carrageenan may exert in direct cytotoxic effects by the 
release of NO, reactive oxygen species, eicosanoids and excitatory amino acids (EAA - glutamate and 
aspartate) EAA [24]. Alternatively, IL-1β induced by carrageenan might sensitize spinal neurons 
through the induction of nociceptive neuropeptides expression, such as substance P (SP) and nerve 
growth factor (NGF). It also has been shown that nociceptive stimulus induced by glutamate, PGs, 
histamine or 5-HT carrageenan-induced release resulted on direct nociceptors sensitization, 
culminating with simultaneous thermal and mechanical hyperalgesia [25]. We showed that acute HA 
administration, all doses, was able to reverse the hyperalgesic response induced by carrageenan, thus 
suggesting a possible inhibitory effect on the inflammatory cascade.  
It is well know that cytokine TNF-α is recognized as a potent pro-inflammatory endogenous 
substance, which is rapidly produced in large quantities by macrophages in response to inflammatory 
stimuli such as bacterial infection [26]. TNF-α interacts with target cells through high-affinity 
membrane receptors, as tumor necrosis factor receptor type 1 (TNFR1 or p55) and type 2 (TNFR2 or 
p75) [27]. Thus, TNF-α-induced hyperalgesia is mediated by prostanoids and sympathetic amines. We 
demonstrated that HA was able to reverse the hyperalgesic response induced by TNF-α, thus 
suggesting a possible inhibitory effect on the inflammatory cascade, as observed with the treatment 
with indomethacin. 
Taking those findings into account, we evaluated whether the antinociceptive activity of hecogenin 
acetate involves the blockade of sensitization or activation of the nociceptor through evaluation of its 
effect on hyperalgesia induced by PGE2 and dopamine [18]. As the hyperalgesia induced by these 
mediators is independent of the final production of other inflammatory mediators or recruitment of 
cells, such as neutrophils [28] and as it has been demonstrated that HA administration was able to 
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maintain the baseline nociceptive threshold, we can then suggest the possibility that HA interacts with 
dopamine or EP receptors; consequently, the paths of its analgesic effects may be through the action 
not only at the inflammatory level but also from a possible involvement of neuronal pathways [29], as 
suggested by Brito et al. [29] and Gama et al. [30].  
In fact, the acute pretreatment with hecogenin acetate increased threshold sensitivity towards 
mechanical stimuli in carrageenan-, TNF-α, PGE2- or dopamine-induced mechanical hyperalgesia, this 
compound is suggested to have produced an inhibition of the inflammatory cascade. Previously,  
Peana et al. [15] and Cerqueira et al. [16] have shown the antiedematogenic and anti-inflammatory effects 
of hecogenin, and they demonstrated that anti-inflammatory activity of hecogenin may be involvement 
inhibitory of cytokines pathway, at least partially. This hypothesis has been confirmed by our results of 
Real Time PCR analysis when we demonstrated that HA treatment could inhibit the expression of IL-1β 
(Figure 3). However, acute treatment with HA did not alter TNF-α (Figure 3B), and IL-6 (Figure 3C); and 
the expression of the anti-inflammatory cytokine IL-10 (Figure 3D). In addition, Cerqueira et al. [16] 
proposed that hecogenin, as non-acetylated, increased COX-2 expression in ethanol-induced gastric ulcer 
in rodents and who also suggest that hecogenin produces beneficial effect in gastric injury through 
mechanisms involving the inhibition of inflammatory cell infiltration and lipid peroxidation, up-regulation 
of the COX-2/PG pathway and K+ATP channels. Differently, we demonstrated that acute treatment with 
HA was not able to change COX-2 expression, by assessed mRNA COX-2 levels (Figure 4). 
Figure 3. Effect of treatment with hecogenin acetate (HA) on IL-1β mRNA (A), TNF-α 
mRNA (B), IL-6 mRNA (C), and IL-10 mRNA (D) paws levels. Mice were injected with 
HA (20 mg/kg) or vehicle (Veh; XX; control group) by the intraperitoneal route 30 min 
before the intraplantar injection of complete Freund’s adjuvant (CFA). The paw levels of 
cytokines were measured by Real Time PCR 2 h after the CFA injection. Data are  
reported as means ± SEM; n = 6 mice per group. * p < 0.05 vs. naive group; # p < 0.05 vs. 
vehicle-treated group, two-way ANOVA followed by Tukey’s test. 
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Figure 4. Effect of treatment with hecogenin on COX-2 mRNA paw levels. Mice were 
injected with hecogenin (HC; 20 mg/kg) or vehicle (Veh; control group) by the 
intraperitoneal route 30 min before the intraplantar injection of complete Freund’s adjuvant 
(CFA). The paw levels of COX-2 mRNA were measured by Real Time PCR 2 h after the 
CFA injection. Data are reported as means ± SEM; n = 6 mice per group. * p < 0.05 vs. 
naive group, one-way ANOVA followed by Tukey’s test. 
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As it is well known, peripheral or central opioid receptor activation could lead to the decrease of the 
pain sensation towards an inflammatory stimulus, through the NO-cGMP-K+ATP channel pathway 
activation [31]. Based on both suggestions that HA promotes regulation of K+ATP channels and the 
inhibitory effect of opioids on the spinal nociceptive transmission, and as our group has recently 
demonstrated, for the first time, that systemic administration of HA, at doses that did not induce motor 
performance alterations, produced consistent antinociceptive effect, probably mediated by opioid 
system and descending pain-inhibitory pathways activation [30], we investigated whether analgesic-
like profile of HA was due to the involvement of spinal cord dorsal horn pathways through 
immunohistochemical approach.  
Ninety minutes after the intraperitoneal injection of HA, the average number of neurons showing 
Fos protein in the spinal cord dorsal horn was significantly (p < 0.05) reduced (Figure 5) at doses of 5, 
10 and 20 mg/Kg when compared with control (Vehicle). 
The superficial dorsal horn of the spinal cord, particularly substantia gelatinosa (SG), is a major 
projection site of small-diameter afferent nerve fibers that predominantly transmit nociceptive signals. 
SG neurons also receive descending inputs from the brainstem [32]. Baba et al. [33] demonstrated 
using an in vitro spinal cord slice preparation that peripheral inflammation can facilitate A-beta  
fiber-mediated synaptic inputs to dorsal horn of the spinal cord, mainly SG, and also produce an 
increase in c-fos expression.  
The protooncogene c-fos, when activated, makes the immunologically detectable nuclear protein 
Fos [34]. A striking attribute of Fos is that it is rapidly expressed in central neurons after noxious 
stimuli [35]. Previous studies demonstrated that the increased c-fos expression is a transient reaction of 
spinal neurons in painful conditions, as in chronic pain [35,36]. The causes of that spinal cord 
nociceptive neuronal hyperactivity during certain types of pain remain unclear. It may derive from the 
constant barrage of peripheral input [37], but may also reflect impairments of descending modulation, 
as previously showed by HA [30]. Anyway, the value of the analysis of Fos expression to monitor the 
nociceptive activity of large neuronal populations is solid [35]. 
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Figure 5. Immunofluorescence for Fos protein in the spinal cord dorsal horn, Ninety 
minutes after the intraperitoneal injection of vehicle (A) hecogenin acetate at doses of 5 
(B), 10 (C) and 20 (D) mg/Kg. The bar graph shows (below and right side) average Fos 
positive cells compared with the vehicle-treated group (white bar) Values represent  
mean ± S.E.M. (n = 6, per group). * p < 0.05, ** p < 0.01 vs. control (one-way ANOVA 
followed by Tukey’s test). 
  
In addition, CNS-depressant drugs, such as gabapentin, frequently used as analgesic in some types 
of painful conditions, inhibit glutamatergic excitatory neurotransmission at the spinal dorsal horn and 
decrease Fos expression when they produce analgesic effect [38]. Thus, our results suggests that the 
inhibition of neuronal hyperactivity at the spinal cord dorsal horn (by a significantly decrease of Fos 
expression) could account for the analgesic efficacy of hecogenin acetate, in all doses tested, in 
carrageenan-induced inflammatory nociception. Hence, it may also decrease neuronal activation at the 
spinal cord horn, by depressing descending facilitation through periaqueductal gray (PAG) activation, 
as previously demonstrated by our group [30].  
Earlier studies suggested that the CNS depression and the non-specific muscle relaxation effects can 
reduce the response of motor coordination and might invalidate the behavioral test results, including 
mechanical hyperalgesic tests [28,39]. Since Brito et al. [29] showed the anxiolytic and antidepressant 
effects of hecogenin and as these activities can induce impair in motor coordination, we assessed that 
acute treatment with HA, at the doses tested, did not have any performance alteration in the rota-rod 
apparatus (data no shown). 
3. Experimental  
3.1. Animals 
All experimental protocols were approved by the Animal Care and Use Committee (CEPA/UFS # 
04/12) at the Federal University of Sergipe, and handling procedures were in accordance with the 
Guide for the Care and Use of Laboratory Animals (NIH - National Institutes of Health) for the use of 
animals in pain research [40]. Male Swiss mice (32–39 g), 2–3 months of age, were used throughout 
this study. The animals were randomly housed in appropriate cages at 21 ± 2 °C on a 12 h light/dark 
cycle (lights on from 6:00 a.m. to 6:00 p.m.) with free access to food (Purina®, Brazil) and water. 
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Before the experiments, the animals were acclimatized to the laboratory for at least 1h. Mice were used 
only once in each test. Experiments were carried out between 9:00 a.m. and 2:00 p.m. in a quiet room. 
All experiments involving the behavioral analysis were carried out by the same visual observer and in 
a double-blind manner. 
3.2. Hyperalgesic Stimulus and Nociceptive Threshold Evaluation 
Mechanical hyperalgesia was tested in mice as reported by Cunha et al. [41], with alterations as 
previously published [39]. In a quiet room, mice were placed in acrylic cages (12 × 10 × 17 cm) with 
wire-grid floors 15–30 min before starting the test. This method consisted of evoking a hindpaw 
flexion reflex with a hand-held force transducer (electronic anesthesiometer, Model EFF 302, Insight®, 
Ribeirão Preto-SP, Brazil) adapted with a polypropylene tip. The investigator was trained to apply the 
tip perpendicularly to the central area of the hindpaw with a gradual increase in pressure. The end 
point was characterized by the paw withdrawal followed by clear flinching movements. After this 
response, the intensity of the pressure was automatically recorded. The intensity of stimulus was 
obtained by averaging four measurements performed with minimal intervals of 3 min. The animals 
were tested before and after treatments.  
Mice were divided into five groups (n = 8, per group), which were treated with vehicle  
(saline + tween 80, 0.2 mL for 1 mL - saline; i.p.), hecogenin acetate (HA, 5, 10 or 20 mg/kg; i.p.), 
indomethacin (10 mg/kg; i.p.) or dipyrone (60 mg/kg; i.p.). Thirty min after treatment, 20 μL of 
carrageenan (300 µg/paw), PGE2 (100 ng/paw), DA (30 μg/paw) or TNF-α (100 pg/paw) were 
injected subcutaneously into the subplantar region of the hindpaw, as described by Cunha et al. [41] 
and Villarreal et al. [18]. The degree of hyperalgesia was evaluated at 0.5, 1, 2, and 3 h after the 
injection of hyperalgesic agents.  
3.3. Motor Function Assay (Rota-Rod Test) 
To evaluate the possible non-specific muscle-relaxant or sedative effects of hecogenin acetate in the 
doses used, mice were submitted to the rota-rod test (AVS®, Brazil) according to Quintans-Junior  
et al. [42]. The animals were selected 24 h previously by eliminating those mice which did not remain 
on the bar for two consecutive periods of 240 s. Mice were pre-treated with diazepam (DZP, 3 mg/kg, 
i.p., reference drug), HA (5, 10 or 20 mg/kg, i.p.) or vehicle (saline + Tween 80, 0.2 mL for 1 mL-saline, 
i.p.) and 1 h later were placed on a rotating rod. The latency to falling was measured up to 180 s. The 
results are expressed as the average time (s) during which the animals remained on the rota-rod 
apparatus in each group. 
3.4. Immunofluorescence  
Ninety minutes after the intraperitoneal injection of HA at doses of 5, 10 and 20 mg/Kg or vehicle 
(Saline + Tween 80, 0.2 mL for 1 mL-saline), the animals (n = 6, per group) were perfused with 
phosphate buffer (0.01 M) saline isotonic (PBS) followed by 10% buffered formalin (100 mM). The 
spinal cord (L4-L6) were removed and stored at −80 °C for the imunofluorescence against Fos protein.  
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The protocol for immunofluorescence was based on prior [43,44]. Frozen serial transverse sections 
(20 µm) of the whole spinal cord were collected on gelatinized glass slides. After washing with PBS, 
the slices were incubated with 0.1 M glycine in PBS for 10 min. Non-specific protein binding was 
blocked by the incubation of the sections for 30 min in a solution containing 2% BSA. Then, the 
sections were incubated overnight with rabbit anti-Fos as primary antibodies (1:2000). Afterwards, the 
sections were incubated for 2 hr with donkey anti-rabbit IgG -Alexa Fluor 594 (1:2000). Sections were 
cover slipped with Fluoromount G. As a control for non-specific labeling, sections were incubated 
without primary antibody. After each stage, slides were washed with PBS five times for 5 min.  
3.5. Acquisition and Analyses of Images 
Light level photomicrographs of spinal cord sections were acquired for each animal with an 
Axioskop 2 plus, Carl Zeiss®, Germany. Neurons were counted by the free software Image J (National 
Institute of Health) using a plug-in (written by the authors) that uses the same level of label intensity to 
select and count the Fos-positive cells.  
3.6. Real Time PCR 
Mice were slightly anesthetized with halothane and received 10 µL of complete Freund’s adjuvant 
(CFA; 1 mg/mL of heat-killed Mycobacterium tuberculosis in 85% paraffin oil and 15% mannide 
monoleate; Sigma, St. Louis, MO, USA) subcutaneously in the plantar region of the right hind paw, 
according to a method reported previously [45]. The transcription of TNF-α (tumor necrosis factor 
alpha), IL-1β (Interleukin 1 beta), IL-6 (Interleukin 6), IL-10 (Interleukin 10) and COX-2 
(cyclooxygenase type 2) genes was evaluated by real-time quantitative polymerase chain reaction 
(qRT-PCR) in mice sacrificed two hours after the CFA injection. Total RNA was isolated from the 
paw tissue with TRIzol reagent (Invitrogen Corporation, Carlsbad, California, CA, USA), and the 
concentration was determined by photometric measurement. High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems, Foster City, CA, USA) was used to synthesize cDNA from 1 μg of RNA 
following the manufacturer’s recommendations. qRT-PCR assays were performed to detect the 
expression levels of IL-1β, TNF-α, IL-6, IL-10 and COX-2 genes. Amplification mixtures for  
qRT-PCR contained 20 ng template cDNA, 10 μL Taqman Master Mix (Applied Biosystems) and 
probes in a final volume of 20 μL. All reactions were run in duplicate on an ABI7500 Sequence 
Detection System (Applied Biosystems) under standard thermal cycling conditions. Experiments with 
coefficients of variation greater than 5% were excluded. A no-template control (NTC) and no-reverse 
transcription controls (No-RT) were also included. The results are presented as the fold-increase of 
expression of the individual mRNAs, with the target internal control GADPH using the cycle  
threshold method.  
3.7. Drugs and Reagents 
λ-Carrageenan, tumor necrosis factor-alpha (TNF-α), prostaglandin E2 (PGE2), dopamine (DA), 
ethylenediamine tetraacetic acid (EDTA), Tween 80, fluoromount G, glycine and bovine serum 
albumin (BSA) and hecogenin acetate (HA, ~90% purity) were purchased from Sigma (Sigma,  
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St. Louis, MO, USA). Indomethacin and dipyrone were purchased from União Quimica (Brazil). c-Fos 
Antibody, a rabbit polyclonal IgG, was obtained from Santa Cruz Biotechnology (Dallas, Texas, TX, 
USA) and Alexa Fluor® 488, a Donkey Anti-Rabbit IgG (H+L), was obtained from Life technology 
(Grand Island, New York, NY, USA). 
3.8. Statistical Analysis 
Data are presented as means ± standard error of the mean (SEM) of measurements made on  
6–8 animals in each group. Comparisons between three or more treatments were made using two-way 
analysis of variance (ANOVA) followed by Tukey’s test. In all cases, differences were considered 
significant if p < 0.05. All statistical analyses were carried out using Graph Pad Prism 5.0 (Graph Pad 
Prism Software Inc., San Diego, CA, USA). 
4. Conclusions  
Together, our results clearly indicate that HA displays significant anti-hyperalgesic effect in animal 
protocols. The precise mechanism by which HA promotes its effects is not clear, but the compound’s 
ability to modulate spinal cord dorsal horn and inhibit IL-1β expression appear to be likely one of the 
possible mechanisms. However, it is possible that another central or peripheral mechanism, not studied 
in present work, may be related to the analgesic effect of hecogenin acetate. Therefore, this steroidal 
sapogenin may be of potential interest in the development of new clinically relevant drugs for the 
management of painful conditions.  
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